Table 1.
Patient characteristics 3 months after transplantation
| Characteristic | All Patients (n=634) | 3-Month 25(OH)D Level < 15 ng/ml (n=348) | 3-Month 25(OH)D Level ≥ 15 ng/ml (n=286) | P Valuea |
|---|---|---|---|---|
| Age at transplantation (yr) | 48.3±13.4 | 48±14 | 50±13 | 0.41 |
| Male sex | 58.7 (372) | 58.0 (202) | 59.4 (170) | 0.72 |
| Initial nephropathy | 0.16 | |||
| Primary GN | 23.2 (147) | 24.1 (84) | 22.0 (63) | |
| Cystic nephropathy | 15.3 (97) | 12.9 (45) | 18.2 (52) | |
| Uropathy | 8.2 (52) | 6.9 (24) | 9.8 (28) | |
| Diabetes | 7.6 (48) | 9.2 (32) | 5.6 (16) | |
| Vascular nephropathy | 6.2 (39) | 6.3 (22) | 5.9 (17) | |
| Interstitial nephropathy | 3.6 (23) | 4.6 (16) | 2.4 (7) | |
| Other | 15.9 (101) | 17.0 (59) | 14.7 (42) | |
| Unknown | 20.0 (127) | 19.0 (66) | 21.3 (61) | |
| Preemptive transplantation | 13.7 (86) | 10.7 (37) | 17.3 (49) | 0.02 |
| Treated by hemodialysis before transplantation | 81.2 (510) | 84.6 (292) | 77.0 (218) | 0.02 |
| Treated by peritoneal dialysis before transplantation | 3.7 (23) | 3.2 (11) | 4.2 (12) | 0.49 |
| Time on dialysis before transplantation (mo) | 35.4 (12.0–73.2) | 38.8 (15.2–76.3) | 30.0 (7.95–69.4) | 0.01 |
| Parathyroidectomy before transplantation | 12.6 (80) | 12.1 (42) | 13.3 (38) | 0.65 |
| Repeat transplantation (for first transplantations) | 77.7 (491) | 77.2 (267) | 78.3 (224) | 0.73 |
| Living donor | 20.8 (131) | 17.7 (61) | 24.6 (70) | 0.04 |
| Donor age (yr) | 53±16 | 53±16 | 53±16 | 0.87 |
| Extended donor criteria | 51.4 (314) | 52.3 (176) | 50.2 (138) | 0.59 |
| Cold ischemia time (min) | 1122 (753–1492) | 1151 (851–1476) | 1090 (492–1500) | 0.15 |
| Delayed graft function | 32.3 (205) | 35.3 (123) | 28.7 (82) | 0.07 |
| Induction treatment | 95.6 (593) | 96.2 (328) | 95.0 (265) | 0.46 |
| Type of induction treatment | 0.78 | |||
| Basiliximab | 69.6 (413) | 68.6 (225) | 70.9 (188) | |
| Antilymphocytic serum | 29.0 (172) | 29.9 (98) | 27.9 (74) | |
| Others | 1.3 (8) | 1.52 (5) | 1.1 (3) | |
| Calcineurin inhibitor–based regimen | 98.5 (605) | 98.8 (333) | 98.2 (272) | 0.65 |
| Cellular acute rejection before 3 mo | 8.2 (52) | 8.62 (30) | 7.69 (22) | 0.67 |
| Humoral acute rejection before 3 mo | 4.6 (29) | 4.02 (14) | 5.24 (15) | 0.46 |
| Body mass index (kg/m2) | 24.1±4.3 | 24.2±4.53 | 24.0±4.09 | 0.55 |
| Systolic BP (mmHg) | 136.2±17.9 | 136.7±17.8 | 135.7±18.0 | 0.48 |
| Diastolic BP (mmHg) | 77.9±10.7 | 77.8±11.1 | 78.1±10.1 | 0.71 |
| mGFR (ml/min) | 57±17 | 57±17 | 58±17 | 0.28 |
| Ionized calcium (mmol/L) | 1.27±0.09 | 1.27±0.09 | 1.27±0.09 | 0.21 |
| Phosphate (mmol/L) | 0.77±0.21 | 0.77±0.22 | 0.77±0.20 | 0.80 |
| 1,25(OH)D (pg/L) | 35 (23–48) | 31 (19–41) | 40 (27–53) | P<0.001 |
| PTH (ng/L) | 98 (64–159) | 111 (78–198) | 81 (55–137) | P<0.001 |
| FGF-23 (RU/ml) | 70 (47–116) | 67 (44–115) | 73 (52–119) | 0.23 |
| Cinacalcet treatment | 3.6 (23) | 3.2 (11) | 4.2 (12) | 0.49 |
Values are reported as percentage (number of patients), mean ± SD, or median (interquartile range), as appropriate.
a
P value represents tests of significance from t test, Wilcoxon test, chi-squared test, or Fisher exact test, as appropriate.